OncoKB: A Precision Oncology Knowledge Base
Debyani Chakravarty, Jianjiong Gao, Sarah M. Phillips et al. · JCO Precision Oncology · 2017
PURPOSE: With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base. METHODS: OncoKB annotates the biological and oncogenic effect and the prognostic and predictive significance of somatic molecular alterations. Potential treatment implications are stratified by the level of evidence that a specific molecular alteration is predictive of drug response based on US Food and Drug Administration (FDA) labeling, National Comprehensive Cancer Network (NCCN) guidelines, disease-focused expert group recommendations and the scientific literature. RESULTS: To date, over 3000 unique mutations, fusions, and copy number alterations in 418 cancer-associated genes have been annotated. To test the utility of OncoKB, we annotated all genomic events in 5983 primary tumor samples in 19 cancer types. Forty-one percent of samples harbored at least one potentially actionable alteration, of which 7.5% were predictive of clinical benefit from a standard treatment. OncoKB annotations are available through a public web resource (http://oncokb.org/) and are also incorporated into the cBioPortal for Cancer Genomics to facilitate the interpretation of genomic alterations by physicians and researchers. CONCLUSION: OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions.
Cited by 2,589 works. doi:10.1200/po.17.00011
Authors
- Debyani Chakravarty
- Jianjiong Gao
- Sarah M. Phillips
- Ritika Kundra
- Hongxin Zhang
- Jiaojiao Wang
- Julia E. Rudolph
- Rona D. Yaeger
- Tara E. Soumerai
- Moriah H. Nissan
- Matthew T. Chang
- Sarat Chandarlapaty
- Tiffany A. Traina
- Paul K. Paik
- Alan Loh Ho
- Feras M. Hantash
- Andrew Grupe
- Shrujal S. Baxi
- Margaret K. Callahan
- Alexandra Snyder
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
- Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
- Comprehensive molecular portraits of human breast tumours
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- Comprehensive molecular characterization of human colon and rectal cancer